These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Multifunctionalized Micelles Facilitate Intracellular Doxorubicin Delivery for Reversing Multidrug Resistance of Breast Cancer.
    Author: Cao A, Ma P, Yang T, Lan Y, Yu S, Liu L, Sun Y, Liu Y.
    Journal: Mol Pharm; 2019 Jun 03; 16(6):2502-2510. PubMed ID: 30998372.
    Abstract:
    Intracellular doxorubicin (DOX) pumping out of cells through the P-glycoprotein (P-gp) transporter leads to the reduction of intracellular DOX levels and induces multidrug resistance (MDR). A hyaluronic acid-deoxycholic acid-histidine and Pluronic F127 (PF127) mixed micellar system, named HA-DOCA-His-PF micelles, functionalized with active targeted endocytosis mediated via CD44 receptor, intracellular triggered DOX release under endosome-pH, and combined with PF127-mediated P-gp efflux inhibition was developed for sufficient intracellular DOX delivery and MDR reversion. The DOX/HA-DOCA-His-PF drug-loaded micelles displayed endosomal pH-mediated self-assembly/disassembly characteristics, triggered DOX release under an endosomal (pH 5.5) environment, and demonstrated enhanced cytotoxicity and superior MDR reversion performance against drug-resistant MCF-7/Adr tumor cells. Importantly, superior antitumor activity of DOX/HA-DOCA-His-PF micelles was presented on the growth inhibition of MCF-7/Adr tumor cells, by further inhibiting the P-gp activity on intracellular DOX efflux through the depletion of intracellular adenosine triphosphate content. This multifunctional micellar system could be facilitated by the intracellular DOX delivery for reversing MDR of breast cancer.
    [Abstract] [Full Text] [Related] [New Search]